ANAB (AnaptysBio) Margin of Safety % (DCF Dividends Based): N/A (As of Jul. 01, 2026)


ANAB AnaptysBio Inc ANAB
66 GF Score
Price $65.43
GF Value $61.32
Valuation Fairly Valued
! 5 Warning Signs
View Full Analysis

What is AnaptysBio Margin of Safety % (DCF Dividends Based)?

Margin of Safety % (DCF Dividends Based) = (Intrinsic Value: DCF (Dividends Based) - Current Price) / Intrinsic Value: DCF (Dividends Based).

Note: Discounted Dividend model is only suitable for companies who have a consistant distribution history with more than 5 years. If the company's dividends does not remain steady over a long period, results may not be accurate due to the low consistency. The model is also only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, the data will not be stored into our database.

AnaptysBio's Predictability Rank is 1-Star. Thus, the DCF related results in the screener and portfolio will appear as zero and Margin of Safety % (DCF Dividends Based) is not calculated.

ANAB vs ABSI, TSHA, RXRX: Margin of Safety % (DCF Dividends Based) Comparison

For the Biotechnology subindustry, AnaptysBio's Margin of Safety % (DCF Dividends Based), along with its competitors' market caps and Margin of Safety % (DCF Dividends Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

AnaptysBio Margin of Safety % (DCF Dividends Based) vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, AnaptysBio's Margin of Safety % (DCF Dividends Based) distribution charts can be found below:

* The bar in red indicates where AnaptysBio's Margin of Safety % (DCF Dividends Based) falls into.


ANAB
66GF Score
AnaptysBio Inc ANAB
Margin of Safety % (DCF Dividends Based) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is AnaptysBio (ANAB) Overvalued in 2026?

Based on GuruFocus' analysis, AnaptysBio stock appears to be overvalued. The current stock price of $65.43 is trading 6.7% above its estimated GF Value™ of $61.32. GuruFocus considers AnaptysBio to be Fairly Valued.

Key valuation signals for ANAB:

  • Margin of Safety % (DCF Dividends Based): N/A
  • GF Value™: $61.32 vs. price of $65.43 (6.7% above fair value)
  • GF Score™: 66/100 with 5 warning signs

No single metric tells the full story. See the ANAB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

AnaptysBio Business Description

Other Exchanges 0HFQ:UKAN6:Germany
Address 10770 Wateridge Circle, Suite 210, San Diego, CA, USA, 92121
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).
66GF Score

Get the complete analysis for ANAB

Margin of Safety % (DCF Dividends Based) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$65.43
Price
$61.32
GF Value